Printed from Voxsanity (voxsanity.com.au) — NCT06954831 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Back to Breast Cancer
Phase 2 Breast Cancer Trial, Recruiting
NCT06954831
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Participants must have provided documented informed consent (themselves or through a legally authorized representative)
- Participants must be aged 40 years or older
- Participants must be female
- Participants must be able to read and understand English to complete study questionnaires
- Participants must have a confirmed breast cancer diagnosis based on tissue testing
- The breast cancer must be of the epithelial type (certain rarer types, such as lymphoma or sarcoma of the breast, are not included)
- Participants must have had breast-conserving surgery (lumpectomy), including cases where a second surgery was done to achieve clear margins
- Participants must have had a surgical procedure to check the lymph nodes under the arm (either a sentinel node biopsy or a full lymph node removal)
- Participants must have at least one high-risk feature that would lead their radiation oncologist to recommend a boost dose of radiation to the lumpectomy area
- A doctor must have rated the cosmetic outcome after lumpectomy as "Good" or "Excellent" using a standard four-point scale, assessed before radiation treatment begins
- Participants of childbearing potential must have a negative pregnancy test (urine or blood) before joining (confirm with trial site for exact definition used)
Who may not be able to join:
- People who have had prior radiation treatment to the affected breast area in a way that, in the investigator's opinion, would prevent further breast radiation
- People whose cancer has spread to nearby lymph nodes in a way that requires a broader type of radiation treatment covering the collarbone area
- People with a serious uncontrolled medical condition
- People with stage IV (advanced/metastatic) breast cancer
- People diagnosed with Paget's disease of the nipple
- People with another current or previous cancer, unless that cancer is unlikely to affect the safety or results of this trial (the trial site would assess this on a case-by-case basis)
- People who are pregnant or breastfeeding
- People who, in the investigator's opinion, may not be able to follow all study procedures and requirements
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Status
Recruiting
Phase
Phase 2
Sponsor
Registry
ClinicalTrials.gov
Start date
28 August 2025
Est. completion
31 January 2028
Where this trial is recruiting
🇺🇸 United States
Primary endpoints
Response rate
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.